| Keyword | CPC | PCC | Volume | Score | Length of keyword |
|---|---|---|---|---|---|
| invitae corp stock price | 0.68 | 0.1 | 907 | 14 | 24 |
| invitae | 0.54 | 0.1 | 285 | 9 | 7 |
| corp | 1.43 | 0.8 | 5480 | 33 | 4 |
| stock | 1.12 | 0.7 | 4508 | 86 | 5 |
| price | 1.63 | 0.4 | 6106 | 18 | 5 |
| Keyword | CPC | PCC | Volume | Score |
|---|---|---|---|---|
| invitae corp stock price | 0.9 | 0.9 | 1879 | 77 |
| invitae corp stock forecast | 1.17 | 0.5 | 2237 | 3 |
| invitae stock price forecast | 0.72 | 0.7 | 2863 | 11 |
| invitae genetics stock price | 0.37 | 0.8 | 2774 | 98 |
| invitae stock motley fool | 1.75 | 1 | 1630 | 59 |
| invitae corporation investor relations | 0.58 | 0.1 | 4166 | 20 |
| what is invitae corp | 0.98 | 0.5 | 6902 | 63 |
| should i buy invitae stock | 0.72 | 0.1 | 8941 | 1 |
| why is invitae stock down | 0.25 | 0.8 | 6498 | 88 |
| what is invitae corporation | 1.17 | 0.4 | 6232 | 73 |
| is invitae a buy | 1.62 | 0.7 | 9350 | 58 |
| how much does invitae cost | 0.41 | 1 | 4402 | 55 |
| davita inc stock price | 1.59 | 0.4 | 8441 | 9 |
| invitae stock forecast 2025 | 0.3 | 0.6 | 8332 | 58 |
| invitae in the news | 1.37 | 0.4 | 6680 | 26 |
| price of davita stock | 0.92 | 0.6 | 4572 | 52 |
| invitae corporation san francisco | 1.07 | 0.6 | 9189 | 81 |
| invitae corporation san francisco ca | 2 | 0.1 | 9643 | 25 |
| invitae corporation 1400 16th street | 0.86 | 0.5 | 6907 | 98 |
| kavita industries share price | 1.94 | 0.8 | 3222 | 41 |
| invitae number of employees | 0.7 | 0.6 | 225 | 88 |
| invitae insurance in network | 1.8 | 1 | 940 | 74 |
Invitae (NVTA) Gets a Buy Rating from Chardan Capital. In a report released yesterday, Steven Wardell from Chardan Capital reiterated a Buy rating on Invitae (NVTA), with a price target of $32.
Does Invitae have a long path to profitability?Despite having a restricting plan in place, the biotech company has a “long path to profitability,” according to Goldman Sachs. The Analyst: Matthew Sykes downgraded the rating for Invitae from Neutral to Sell, while reducing the price target from $4 to $2. Check out other analyst stock ratings.
What is Invitae Corp?Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.
Is Invitae poised to re-accelerate growth?Invitae seems to have “a long and uncertain path towards profitability and a gross margin profile that will make it difficult to deploy opex in order to re-accelerate growth,” the analyst added.
